India Glycols Limited — Investor Meet, 21-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

The company reported strong Q2 and H1 FY26 financial results. Q2 net revenue grew 14% and EBITDA surged 33%, with PAT up 31%. H1 saw similar healthy growth across top-line and profitability. Biofuels and Potable Spirits segments were key drivers, showing significant revenue and EBIT margin expansion. The Chemicals business faced weak sales but improved margins due to better product mix and focus on value-added green chemicals. Ennature Biopharma faced challenges, but management is focused on branded nutraceuticals and global certifications. The company will use funds from a preferential allotment for debt reduction, expecting lower finance costs. Management expressed a confident outlook on growth.